Cargando…
Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) gene mutation is present in ~20% of patients with de novo acute myeloid leukemia (AML). Patients with an FLT3-ITD mutation have a poor prognosis. However, the prognostic function of FLT3-ITD combined with other cytogenetic abnorma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876342/ https://www.ncbi.nlm.nih.gov/pubmed/31807186 http://dx.doi.org/10.3892/ol.2019.11051 |
_version_ | 1783473191979581440 |
---|---|
author | Tao, Shandong Wang, Chunling Chen, Yue Deng, Yuan Song, Lixiao Shi, Yuyue Ling, Lanlan Ding, Banghe He, Zhengmei Yu, Liang |
author_facet | Tao, Shandong Wang, Chunling Chen, Yue Deng, Yuan Song, Lixiao Shi, Yuyue Ling, Lanlan Ding, Banghe He, Zhengmei Yu, Liang |
author_sort | Tao, Shandong |
collection | PubMed |
description | The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) gene mutation is present in ~20% of patients with de novo acute myeloid leukemia (AML). Patients with an FLT3-ITD mutation have a poor prognosis. However, the prognostic function of FLT3-ITD combined with other cytogenetic abnormalities are not clear. In the present study, a retrospective analysis of 103 newly diagnosed patients with AML was performed. The results revealed that the overall survival (OS) and recurrence-free survival (RFS) times were significantly longer in patients with an FLT3-ITD mutation combined with other favorable risk genes, compared with in those patients with a single FLT3-ITD mutation (P=0.0361 and P=0.0426). Sorafenib combined with chemotherapy significantly improved the overall response rate (ORR) when compared with mono-chemotherapy (P=0.039), but no significant differences were observed in the OS and RFS. In conclusion, favorable-risk cytogenetics may improve the clinical outcomes of patients with FLT3-ITD-mutated AML, but adverse-risk cytogenetics may not further worsen the prognosis. Sorafenib combined with chemotherapy may increase the ORR but would not result in a longer OS and RFS. |
format | Online Article Text |
id | pubmed-6876342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-68763422019-12-05 Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics Tao, Shandong Wang, Chunling Chen, Yue Deng, Yuan Song, Lixiao Shi, Yuyue Ling, Lanlan Ding, Banghe He, Zhengmei Yu, Liang Oncol Lett Articles The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) gene mutation is present in ~20% of patients with de novo acute myeloid leukemia (AML). Patients with an FLT3-ITD mutation have a poor prognosis. However, the prognostic function of FLT3-ITD combined with other cytogenetic abnormalities are not clear. In the present study, a retrospective analysis of 103 newly diagnosed patients with AML was performed. The results revealed that the overall survival (OS) and recurrence-free survival (RFS) times were significantly longer in patients with an FLT3-ITD mutation combined with other favorable risk genes, compared with in those patients with a single FLT3-ITD mutation (P=0.0361 and P=0.0426). Sorafenib combined with chemotherapy significantly improved the overall response rate (ORR) when compared with mono-chemotherapy (P=0.039), but no significant differences were observed in the OS and RFS. In conclusion, favorable-risk cytogenetics may improve the clinical outcomes of patients with FLT3-ITD-mutated AML, but adverse-risk cytogenetics may not further worsen the prognosis. Sorafenib combined with chemotherapy may increase the ORR but would not result in a longer OS and RFS. D.A. Spandidos 2019-12 2019-11-05 /pmc/articles/PMC6876342/ /pubmed/31807186 http://dx.doi.org/10.3892/ol.2019.11051 Text en Copyright: © Tao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Tao, Shandong Wang, Chunling Chen, Yue Deng, Yuan Song, Lixiao Shi, Yuyue Ling, Lanlan Ding, Banghe He, Zhengmei Yu, Liang Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics |
title | Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics |
title_full | Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics |
title_fullStr | Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics |
title_full_unstemmed | Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics |
title_short | Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics |
title_sort | prognosis and outcome of patients with acute myeloid leukemia based on flt3-itd mutation with or without additional abnormal cytogenetics |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876342/ https://www.ncbi.nlm.nih.gov/pubmed/31807186 http://dx.doi.org/10.3892/ol.2019.11051 |
work_keys_str_mv | AT taoshandong prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT wangchunling prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT chenyue prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT dengyuan prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT songlixiao prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT shiyuyue prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT linglanlan prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT dingbanghe prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT hezhengmei prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics AT yuliang prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics |